Hanmi Semiconductor Climbs After Media Reports of Possible Deal With Micron
By Kwanwoo Jun
Hanmi Semiconductor's shares climbed following media reports of a possible deal to supply chip-making equipment to Micron Technology.
Shares of the South Korean chip-packaging and testing equipment maker rose as much as 22% to 139,100 won ($102.99) in late trade Thursday, outperforming the benchmark Kospi's 0.3% fall.
Hanmi's shares have been up for the fourth consecutive day, riding the artificial-intelligence wave that has led to investor bets on strong demand for AI chips like the high bandwidth memory products from Micron and SK Hynix.
Hanmi's latest rally comes in the wake of South Korean media reports overnight that the company is negotiating a deal to supply high bandwidth memory packaging equipment to Micron, which could place an initial order as early as the second quarter.
Both Hanmi and Micron weren't immediately available for comment on the media reports.
A Hanmi-Micron deal, if finalized, would help the South Korean company expand its Asia-focused customer base to the U.S. Hanmi last week secured a KRW21.48 billion contract from SK Hynix--the latest in a series of recent deals valued around KRW200 billion in total.
Market analysts expect Hanmi to benefit from strong HBM demand in the U.S., as Washington pushes for an onshore AI-chip supply chain, which also involves SK Hynix.
Write to Kwanwoo Jun at kwanwoo.jun@wsj.com
(END) Dow Jones Newswires
March 28, 2024 02:30 ET (06:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth